Tumor Marker Testing Market Report 2026

Tumor Marker Testing Market Overview

• Tumor Marker Testing market size has reached to $18.6 billion in 2025 • Expected to grow to $27.23 billion in 2030 at a compound annual growth rate (CAGR) of 7.9% • Growth Driver: Rising Cancer Prevalence Driving Growth In Tumor Marker Testing Market • Market Trend: Advancements In Tumor Marker Testing Enhanced Market Growth • North America was the largest region in 2025.

What Is Covered Under Tumor Marker Testing Market?

Tumor marker testing refers to the use of specific substances, often proteins, produced by cancer cells or by the body in response to cancer to detect and monitor tumors. These tests help in diagnosing cancer, assessing treatment effectiveness, and checking for recurrence. They are typically performed on blood, urine, or tissue samples. The main products of tumor marker testing are biochemical markers, oncogenes, growth factors, hormones, colony-stimulating factors, lymphokines, immunohistochemical stains, and others. Biochemical markers refer to measurable substances in the body, such as proteins or enzymes, that indicate biological or pathological processes, often used for diagnosing or monitoring diseases. Tumor marker testing is performed through methods such as screening, imaging, theranostics, and sigmoidoscopy. It is applied in various settings, including hospitals, commercial or private laboratories, physician offices or group practices, cancer clinics, and ambulatory care centers.

What Is The Tumor Marker Testing Market Growth Forecast?

The tumor marker testing market size is expected to see strong growth in the next few years. It will grow to $27.23 billion in 2030 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to rising demand for early cancer detection, increasing adoption of precision oncology approaches, expansion of companion diagnostics, growing use of biomarkers in therapy selection, advancements in cancer biomarker research. Major trends in the forecast period include increasing adoption of multiplex tumor marker panels, rising use of blood-based cancer diagnostics, growing integration of tumor markers in treatment monitoring, expansion of early cancer screening programs, enhanced focus on personalized oncology care.

Global Tumor Marker Testing Market Segmentation

1) By Product: Biochemical Markers, Oncogenes, Growth Factors, Hormones, Colony Stimulating Factors, Lymphokines 2) By Methods: Screening, Imaging, Theranostics, Other Methods 3) By Application: Hospitals, Commercial Or Private Laboratories, Physician Offices Or Group Practices, Cancer Clinics, Ambulatory Care Centers Subsegments: 1) By Biochemical Markers: Alpha-fetoprotein (AFP), Prostate-Specific Antigen (PSA), Carcinoembryonic Antigen (CEA), Cancer Antigen 125 (CA 125), Cancer Antigen 19-9 (CA 19-9), Human Chorionic Gonadotropin (hCG) 2) By Oncogenes: HER2 Or neu, KRAS, BRAF, EGFR (Epidermal Growth Factor Receptor), c-MYC, p53 3) By Growth Factors: Vascular Endothelial Growth Factor (VEGF), Platelet-Derived Growth Factor (PDGF), Transforming Growth Factor-beta (TGF-β), Fibroblast Growth Factor (FGF), Insulin-like Growth Factor (IGF) 4) By Hormones: Estrogen Receptors (ER), Progesterone Receptors (PR), Thyroglobulin, Calcitonin, Adrenocorticotropic Hormone (ACTH), Gastrin 5) By Colony Stimulating Factors: Granulocyte Colony-Stimulating Factor (G-CSF), Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF), Macrophage Colony-Stimulating Factor (M-CSF) 6) By Lymphokines: Interleukin-2 (IL-2), Interferon-gamma (IFN-γ), Tumor Necrosis Factor-alpha (TNF-α), Interleukin-6 (IL-6)

What Is The Driver Of The Tumor Marker Testing Market?

The increasing cancer prevalence is expected to propel the growth of the tumor marker testing market going forward. Cancer is a disease characterized by the uncontrolled growth of abnormal cells in the body. These cells can invade nearby tissues and spread to other parts of the body through the blood and lymph systems. Cancer rates are rising due to factors such as aging populations, increased environmental exposures, lifestyle changes, and improved detection and diagnosis. Tumor marker testing is used to diagnose, monitor treatment response, and detect recurrence in various cancers by measuring specific substances produced by cancer cells. For instance, in October 2025, according to the National Health Service, a Uk-based government agency, in 2023, there were 354,820 new cancer diagnoses, or 972 per day on average, 8,605 higher than in 2022. Therefore, the increasing cancer prevalence is driving the growth of the tumor marker testing industry.

Key Players In The Global Tumor Marker Testing Market

Major companies operating in the tumor marker testing market are Thermo Fisher Scientific Inc., Abbott Laboratories, F. Hoffmann-La Roche AG, Danaher Corporation, Siemens Healthineers AG, Becton Dickinson and Company (BD), Quest Diagnostics Inc., Agilent Technologies Inc, Hologic Inc., Illumina Inc., bioMérieux SA, Bio-Rad Laboratories Inc., Qiagen N.V., DiaSorin S.p.A., Myriad Genetics, Ortho Clinical Diagnostics PLC, Veracyte Inc., Biodesix Inc., Biocept Inc., Proteomedix AG, OncoCyte Corporation, Biocartis NV

Global Tumor Marker Testing Market Trends and Insights

Major companies operating in the tumor marker testing market are increasing their focus on developing advanced tests, such as molecular testing solutions, to gain a competitive edge in the market. Molecular testing solutions refer to advanced diagnostic methods that analyze genetic material (DNA or RNA) to detect mutations, pathogens, or specific biomarkers at a molecular level. For instance, in April 2024, RGCC International GmbH, a Switzerland-based company in personalized cancer treatment, launched Onco-D-clare, a groundbreaking cancer detection test. This innovative test enables people to detect cancer before symptoms appear by leveraging the combination of molecular biology and artificial neural networks. Onco-D-clare works by isolating peripheral blood mononuclear cells from blood samples and then conducting comprehensive gene expression analysis across more than 90 genes.

What Are Latest Mergers And Acquisitions In The Tumor Marker Testing Market?

In June 2023, Quest Diagnostics, a US-based clinical laboratory, acquired Haystack Oncology for $300 million. This acquisition aims to enhance cancer diagnostics through the integration of highly sensitive minimal residual disease (MRD) testing technology. Additionally, this acquisition not only strengthens Quest's diagnostic capabilities but also aims to provide more personalized and effective cancer care solutions through innovative liquid biopsy technology. Haystack Oncology is a US-based biotechnology company.

Regional Outlook

North America was the largest region in the tumor marker testing market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Tumor Marker Testing Market?

The tumor marker testing market consists of revenues earned by entities by providing services such as genetic testing, prostate-specific antigen (PSA) tests, and dehydrogenase (LDH) tests. The market value includes the value of related goods sold by the service provider or included within the service offering. The tumor marker testing market also includes sales of test kits, instrumentation, consumables, and reagents. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Tumor Marker Testing Market Report 2026?

The tumor marker testing market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the tumor marker testing industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.